If you’ve been following the incretin drug space at all, you’ve probably noticed the buzz shifting from tirzepatide to something newer: retatrutide. One is already sitting on pharmacy shelves. The other is still working its way through late-stage clinical trials, generating headlines for weight-loss numbers that outpace anything currently approved. So how do they actually compare, and should the excitement around retatrutide change how you think about tirzepatide today? Here’s a clear, evidence-based breakdown of both drugs.
The Core Difference: Dual Agonist vs. Triple Agonist
The biggest distinction between these two drugs comes down to how many hormone receptors they activate.
Tirzepatide (brand names Mounjaro for type 2 diabetes and Zepbound for obesity) is a dual agonist, meaning it activates two hormone receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Together, these hormones slow digestion, reduce appetite, and improve insulin sensitivity.
Retatrutide (Eli Lilly’s investigational compound LY3437943) goes a step further as a triple agonist, activating GLP-1 and GIP just like tirzepatide, plus a third receptor: glucagon. Adding glucagon receptor activity is believed to increase energy expenditure on top of appetite suppression, which researchers believe is the primary driver behind retatrutide’s stronger weight-loss results in trials so far.
Think of it as tirzepatide’s core mechanism with an added metabolic lever, one that pushes the body to burn more energy rather than only eating less of it.
Weight Loss Results: What the Trials Actually Show
This is where the two drugs diverge the most, though it’s important to note that head-to-head trial data is still limited, so most current comparisons rely on separate trials rather than the same study population.
Tirzepatide’s landmark SURMOUNT-1 trial showed an average weight loss of around 21% at 72 weeks in adults with obesity, with other tirzepatide trials showing results generally in the 15% to 21% range depending on dose and population.
Retatrutide’s Phase 3 TRIUMPH program has reported considerably higher numbers. The TRIUMPH-1 trial found that the 12 mg dose produced an average body-weight reduction of roughly 28% at 80 weeks, with a substantial share of participants losing 30% or more of their body weight. Earlier Phase 2 data showed similar patterns, with average weight loss around 24% at 48 weeks. In a diabetes-specific trial, retatrutide’s weight-loss results were notably lower, around 17%, which is a pattern consistent across the entire GLP-1 drug class — weight loss tends to be less pronounced in people with type 2 diabetes than in people with obesity alone.
It’s worth flagging that Eli Lilly is running a direct head-to-head trial comparing the two drugs, with results expected around the end of 2026. Until that data is available, all current comparisons are considered cross-trial estimates rather than a true apples-to-apples comparison, so the actual gap between the two drugs could look somewhat different once head-to-head data is published.
Beyond Weight Loss: Other Metabolic Effects
Both drugs show benefits that extend past the number on the scale, though retatrutide’s added glucagon activity appears to produce some additional effects.
Retatrutide trials have reported meaningful reductions in liver fat, with some data showing substantial improvement in markers relevant to fatty liver disease, alongside improvements in several cardiometabolic risk markers like blood pressure and cholesterol. Tirzepatide has a well-documented track record of improving blood sugar control, blood pressure, and lipid profiles as well, and it carries FDA approval specifically for type 2 diabetes management in addition to weight loss, giving it years of accumulated real-world outcome data that retatrutide simply doesn’t have yet.
Safety Profile: What We Know So Far
Both drugs belong to the same general drug class and share a broadly similar side effect profile, largely centered on the gastrointestinal system: nausea, diarrhea, constipation, and vomiting are the most commonly reported side effects for both, particularly during dose escalation.
Tirzepatide’s safety profile is well-established, with multiple years of real-world prescribing data across millions of patients backing up its clinical trial results. Retatrutide’s safety data, while reassuring so far across its Phase 2 and Phase 3 trials, is inherently more limited simply because it hasn’t been used outside of controlled trial settings or for an extended period at scale. The added glucagon receptor activity is a genuinely new mechanism in this class of drugs, and while trial data hasn’t raised major red flags, any subtle long-term effects specific to that third receptor pathway will only become fully clear with more time and broader use.
FDA Approval Status and Availability
This is the most important practical difference between the two drugs. Tirzepatide is FDA-approved and currently available by prescription as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, meaning your doctor can prescribe it today if it’s appropriate for your health profile.
Retatrutide remains investigational and is not FDA-approved. It’s currently completing its Phase 3 TRIUMPH program, and Eli Lilly has indicated plans to file for FDA approval following the completion of that program. Based on typical timelines for regulatory review after an application is filed, most industry analysts project retatrutide approval sometime in late 2027, with commercial availability likely following in 2028. Those timelines depend entirely on trial results continuing to hold up and the regulatory process proceeding without delays, so they remain estimates rather than guarantees.
Because retatrutide isn’t approved, the only legitimate way to access it currently is through enrollment in an ongoing clinical trial. Compounded or gray-market versions of investigational peptides carry significant risk, since they aren’t manufactured, tested, or regulated the same way an approved medication is, and their actual contents and purity can’t be verified the way a pharmacy-dispensed prescription can.
Should You Wait for Retatrutide Instead of Starting Tirzepatide?
This is a common question, and the honest answer is that it depends on your individual situation and timeline. Tirzepatide is proven, available now, and has years of real-world data behind its safety and effectiveness. Waiting one to two years for a drug that isn’t guaranteed to receive approval on any particular timeline means postponing treatment that could meaningfully improve your health today, particularly if you’re managing obesity-related health conditions where earlier intervention tends to produce better outcomes.
For people who’ve already tried tirzepatide and experienced a plateau or insufficient response, retatrutide’s stronger trial results are a legitimate reason for optimism about future options, but switching isn’t currently possible outside of trial enrollment. This is a conversation worth having directly with your prescribing doctor, who can weigh your specific health history, current response to treatment, and realistic expectations about retatrutide’s approval timeline.
Cost Considerations
Tirzepatide’s cost varies significantly depending on insurance coverage, with list prices running into the four figures per month without insurance, though manufacturer savings programs and insurance coverage can substantially reduce out-of-pocket costs for eligible patients. Since retatrutide isn’t commercially available, there’s no established retail pricing yet, though drugs in this class have generally launched at premium price points, and coverage decisions from insurers typically lag behind FDA approval by additional months.
Frequently Asked Questions
Is retatrutide stronger than tirzepatide for weight loss? Based on separate clinical trials, retatrutide has shown greater average weight loss than tirzepatide, with figures in the upper-20% range compared to tirzepatide’s roughly 15% to 21% range. A direct head-to-head trial is underway, with results expected around the end of 2026, which will provide a more definitive comparison.
Can I get a prescription for retatrutide right now? No. Retatrutide is not yet FDA-approved and can currently only be accessed through enrollment in an ongoing clinical trial. It is not legally available by prescription outside of that setting.
What’s the main mechanism difference between the two drugs? Tirzepatide activates two hormone receptors, GLP-1 and GIP. Retatrutide activates those same two receptors plus a third, glucagon, which is believed to increase energy expenditure and contribute to its stronger weight-loss results in trials.
When will retatrutide be FDA-approved? Retatrutide is still completing its Phase 3 TRIUMPH clinical trial program. Based on typical regulatory review timelines following a completed trial program and FDA filing, most projections estimate approval sometime in late 2027, though this depends on trial outcomes and the regulatory process.
Are the side effects of retatrutide and tirzepatide similar? Yes, both drugs share a similar gastrointestinal side effect profile, including nausea, diarrhea, and constipation, particularly during dose escalation. Tirzepatide has a longer track record of real-world safety data, while retatrutide’s safety profile, though reassuring in trials so far, is still based on a more limited period of study.
Key Takeaways
Tirzepatide and retatrutide represent two generations of the same underlying science: incretin-based therapies that help the body manage appetite, blood sugar, and metabolism. Tirzepatide is the proven, currently available option with a substantial real-world track record. Retatrutide’s early trial results are genuinely impressive, adding a third hormone target that appears to push weight-loss results meaningfully higher, but it remains investigational and inaccessible outside of clinical trials for at least the next year or two.
If you’re weighing your options for medical weight management, the right next step is a conversation with your doctor about whether tirzepatide is appropriate for your health profile today, rather than waiting on a drug with an uncertain approval timeline. Reading a broader guide on how GLP-1 and GIP medications work, or comparing tirzepatide to other approved options like semaglutide, can help round out the full picture before that conversation.